Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 43 | 2024 | 1891 | 4.690 |
Why?
|
| Anti-Retroviral Agents | 12 | 2018 | 140 | 3.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2020 | 241 | 2.270 |
Why?
|
| Malawi | 29 | 2023 | 397 | 1.670 |
Why?
|
| Pregnancy Complications, Infectious | 11 | 2021 | 450 | 1.610 |
Why?
|
| Child Health Services | 5 | 2018 | 85 | 1.300 |
Why?
|
| Mass Screening | 7 | 2020 | 781 | 1.130 |
Why?
|
| Counseling | 7 | 2023 | 216 | 1.060 |
Why?
|
| Anti-HIV Agents | 14 | 2023 | 316 | 1.050 |
Why?
|
| Health Personnel | 8 | 2021 | 503 | 1.050 |
Why?
|
| Tuberculosis | 3 | 2020 | 521 | 0.830 |
Why?
|
| Burnout, Professional | 2 | 2019 | 117 | 0.690 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2016 | 267 | 0.680 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2018 | 235 | 0.670 |
Why?
|
| Community Health Workers | 4 | 2017 | 67 | 0.630 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 41 | 0.570 |
Why?
|
| Family Characteristics | 1 | 2017 | 72 | 0.540 |
Why?
|
| Community Health Services | 1 | 2017 | 89 | 0.530 |
Why?
|
| Quality of Health Care | 2 | 2018 | 388 | 0.530 |
Why?
|
| Infection Control | 1 | 2017 | 154 | 0.520 |
Why?
|
| Health Policy | 1 | 2018 | 213 | 0.520 |
Why?
|
| Chemoprevention | 1 | 2015 | 57 | 0.480 |
Why?
|
| Hearing Loss | 1 | 2016 | 134 | 0.480 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 225 | 0.470 |
Why?
|
| Cross Infection | 1 | 2017 | 323 | 0.460 |
Why?
|
| Antitubercular Agents | 1 | 2016 | 247 | 0.450 |
Why?
|
| Social Work | 1 | 2013 | 20 | 0.440 |
Why?
|
| Pregnancy | 18 | 2023 | 7179 | 0.430 |
Why?
|
| Breast Feeding | 2 | 2023 | 218 | 0.430 |
Why?
|
| Medication Adherence | 6 | 2023 | 396 | 0.420 |
Why?
|
| Child | 22 | 2021 | 24361 | 0.390 |
Why?
|
| Sarcoma, Kaposi | 3 | 2018 | 119 | 0.390 |
Why?
|
| Adolescent | 18 | 2024 | 19253 | 0.350 |
Why?
|
| Humans | 46 | 2024 | 124240 | 0.340 |
Why?
|
| Female | 35 | 2024 | 66304 | 0.330 |
Why?
|
| Pregnant Women | 5 | 2022 | 142 | 0.320 |
Why?
|
| Child, Preschool | 14 | 2019 | 13997 | 0.310 |
Why?
|
| AIDS Serodiagnosis | 3 | 2019 | 56 | 0.300 |
Why?
|
| Adult | 19 | 2024 | 29359 | 0.290 |
Why?
|
| Leishmania infantum | 2 | 2006 | 3 | 0.280 |
Why?
|
| Infant | 15 | 2019 | 12465 | 0.280 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2006 | 18 | 0.270 |
Why?
|
| Early Diagnosis | 3 | 2018 | 180 | 0.270 |
Why?
|
| Protozoan Vaccines | 2 | 2006 | 95 | 0.260 |
Why?
|
| Male | 24 | 2024 | 61023 | 0.250 |
Why?
|
| Depression | 4 | 2022 | 1215 | 0.250 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 115 | 0.250 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3415 | 0.240 |
Why?
|
| Iodine Radioisotopes | 1 | 2024 | 75 | 0.220 |
Why?
|
| Long-Term Care | 2 | 2013 | 69 | 0.210 |
Why?
|
| Thyroidectomy | 1 | 2024 | 100 | 0.210 |
Why?
|
| Preventive Health Services | 2 | 2013 | 60 | 0.210 |
Why?
|
| Infant, Newborn | 8 | 2021 | 8189 | 0.200 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 605 | 0.190 |
Why?
|
| Young Adult | 9 | 2024 | 9000 | 0.190 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 190 | 0.190 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 25 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2013 | 121 | 0.180 |
Why?
|
| Audiovisual Aids | 1 | 2020 | 24 | 0.170 |
Why?
|
| Type D Personality | 1 | 2019 | 2 | 0.170 |
Why?
|
| Viral Load | 2 | 2018 | 384 | 0.170 |
Why?
|
| Marital Status | 1 | 2019 | 32 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2019 | 78 | 0.160 |
Why?
|
| Pediatrics | 2 | 2018 | 1159 | 0.160 |
Why?
|
| Syphilis | 1 | 2019 | 96 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2041 | 0.140 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 142 | 0.140 |
Why?
|
| Health Services Research | 1 | 2018 | 187 | 0.140 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2016 | 15 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2018 | 419 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1422 | 0.130 |
Why?
|
| Sex Factors | 1 | 2019 | 1277 | 0.120 |
Why?
|
| Self Report | 4 | 2020 | 512 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2016 | 3431 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 3687 | 0.120 |
Why?
|
| Family | 1 | 2018 | 562 | 0.120 |
Why?
|
| Prevalence | 2 | 2019 | 2445 | 0.120 |
Why?
|
| Risk Factors | 3 | 2019 | 10248 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 585 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 418 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2022 | 819 | 0.120 |
Why?
|
| Antigens, Protozoan | 2 | 2006 | 65 | 0.120 |
Why?
|
| Maternal Health Services | 2 | 2013 | 37 | 0.110 |
Why?
|
| Coinfection | 1 | 2016 | 171 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 473 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2015 | 160 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 380 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 261 | 0.110 |
Why?
|
| Child, Orphaned | 1 | 2013 | 18 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1031 | 0.110 |
Why?
|
| Public Policy | 1 | 2013 | 51 | 0.110 |
Why?
|
| Immunization Programs | 1 | 2013 | 63 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 1252 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12289 | 0.100 |
Why?
|
| Health Resources | 1 | 2013 | 116 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 4344 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 140 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 206 | 0.100 |
Why?
|
| Developing Countries | 1 | 2013 | 270 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 329 | 0.090 |
Why?
|
| Lost to Follow-Up | 3 | 2018 | 32 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 388 | 0.090 |
Why?
|
| Psychometrics | 1 | 2014 | 666 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2013 | 372 | 0.090 |
Why?
|
| Video Recording | 2 | 2023 | 182 | 0.090 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 10 | 0.080 |
Why?
|
| Contact Tracing | 2 | 2021 | 54 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16293 | 0.080 |
Why?
|
| Age Factors | 1 | 2016 | 2808 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2021 | 1369 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2016 | 722 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 6283 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1213 | 0.080 |
Why?
|
| Malnutrition | 1 | 2012 | 204 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 231 | 0.080 |
Why?
|
| Capacity Building | 2 | 2021 | 24 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 865 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 511 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1585 | 0.070 |
Why?
|
| Quality of Life | 1 | 2016 | 1900 | 0.070 |
Why?
|
| Dog Diseases | 1 | 2006 | 49 | 0.070 |
Why?
|
| Disclosure | 2 | 2017 | 148 | 0.060 |
Why?
|
| Thyroglobulin | 1 | 2024 | 7 | 0.060 |
Why?
|
| Middle East | 1 | 2024 | 34 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2018 | 803 | 0.050 |
Why?
|
| World Health Organization | 2 | 2013 | 101 | 0.050 |
Why?
|
| Prenatal Care | 2 | 2019 | 348 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 66 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 47 | 0.050 |
Why?
|
| Program Development | 2 | 2013 | 186 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 253 | 0.050 |
Why?
|
| Virulence | 1 | 2003 | 262 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5129 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 4609 | 0.050 |
Why?
|
| Tanzania | 1 | 2020 | 68 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1002 | 0.040 |
Why?
|
| HIV-1 | 2 | 2016 | 465 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1799 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 517 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 276 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 81 | 0.040 |
Why?
|
| Global Health | 2 | 2013 | 559 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2013 | 428 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 55 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2018 | 49 | 0.040 |
Why?
|
| Family Health | 1 | 2019 | 258 | 0.040 |
Why?
|
| Depersonalization | 1 | 2018 | 8 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 117 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 132 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 87 | 0.040 |
Why?
|
| Stereotyping | 1 | 2017 | 19 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 221 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 777 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 607 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 588 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 150 | 0.030 |
Why?
|
| Bullying | 1 | 2015 | 13 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 754 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 110 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 299 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 191 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1104 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1491 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1233 | 0.030 |
Why?
|
| United Nations | 1 | 2013 | 12 | 0.030 |
Why?
|
| Schools | 1 | 2015 | 219 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 43 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 866 | 0.030 |
Why?
|
| Lesotho | 1 | 2012 | 17 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 251 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 343 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 566 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 267 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 661 | 0.020 |
Why?
|
| Community Networks | 1 | 2012 | 32 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 382 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2012 | 52 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 32 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 225 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 509 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2011 | 69 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 442 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 469 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 313 | 0.020 |
Why?
|
| Health Promotion | 1 | 2013 | 387 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2011 | 174 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2143 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1320 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1228 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 6118 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 711 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2006 | 75 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19537 | 0.020 |
Why?
|
| Mice | 1 | 2003 | 17625 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 153 | 0.020 |
Why?
|
| Animals | 2 | 2006 | 34046 | 0.020 |
Why?
|
| Dogs | 1 | 2006 | 767 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 325 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 26601 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 501 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 690 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 680 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 4779 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 1289 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2815 | 0.010 |
Why?
|